Antibodies News and Research

RSS

New genetic condition that raises vulnerability to opportunistic infections

An international consortium co-led by Vanderbilt University Medical Center immunogeneticist Rubén Martínez-Barricarte, PhD, has discovered a new genetic disorder that causes immunodeficiency and profound susceptibility to opportunistic infections including life-threatening fungal pneumonia.

24 Jan 2023

Blending multiple maps uncover new genetic causes of blindness

In a new study, Ran Elkon and Ruth Ashery-Padan of Tel Aviv University, Israel, and colleagues discovered a new genetic risk factor for adult-onset macular degeneration (AMD) by combining a map of gene regulatory sites with disease-associated loci.

18 Jan 2023

New revelations on the immune system’s defenses against infections

Cells competing for a place in a germinal center confront a tough admissions process. Germinal centers, which form following exposure to a pathogen or vaccine, serve as a kind of immune system training academy, assisting B cells in refining their response to the threat.

18 Jan 2023

Electrochemical biosensor for detecting antibodies

Although it frequently necessitates a challenging laboratory procedure, the quantitative detection of specific antibodies in complex samples like blood can provide information on a variety of diseases.

18 Jan 2023

Ultrafast, highly sensitive detection of proteins using simple laser irradiation

Protein detection based on antigen–antibody reaction is vital in early diagnosis of a wide range of diseases. How to effectively detect proteins, however, has frequently bedeviled researchers.

4 Jan 2023

Improving cancer immunotherapies with bioengineered synthetic gene circuits

In two distinct studies, scientists show how synthetic biology can be used to address a challenging problem in cancer immunotherapy: the way immunotherapy-related approaches focused on the short-term killing of tumor cells could fail to eradicate tumors because tumor growth occurs on longer timescales.

19 Dec 2022

The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

...

From The Native Antigen Company 8 Dec 2022

Microglial cells trigger inflammatory protective mechanisms in the immune system

Microglia, the brain’s own immune cells, are present in the central nervous system.

1 Dec 2022

Insight into the treatment for Crimean Congo Hemorrhagic Fever Virus

The Crimean Congo Hemorrhagic Fever Virus can be prevented by therapeutically relevant human monoclonal antibodies, according to research led by the University of California, Riverside.

30 Nov 2022

AI creates artificial DNA to control cell protein production

Researchers at Chalmers University of Technology in Sweden have developed synthetic DNA that uses artificial intelligence to control the production of proteins in cells.

25 Nov 2022

Applied Cells Inc. and GenScript enter strategic collaboration to deliver combined solutions for cell therapy development

November 18th, 2022. Today, Applied Cells Inc. and GenScript USA Incorporated announced their strategic collaboration to deliver combined cell isolation solutions for cell therapy drug development worldwide. Under this collaboration, GenScript will develop and supply its proprietary research and cGMP grade CytoSinct™ reagents for use in developing CAR-T and other Cell Therapy products on the Applied Cells MARS® Platform.

25 Nov 2022

Improving potential of cellular therapies with CAR T therapy

CAR T cells, or engineered immune cells, have demonstrated to the world the potential of customized immunotherapies to treat blood cancers. Researchers have just released highly encouraging preliminary data for CAR T therapy in a small group of lupus patients.

25 Nov 2022

Novel approach increases the protein production efficiency of synthetic mRNAs

A group of synthetic biologists at the Hong Kong University of Science and Technology (HKUST) recently figured out a way to improve the efficiency of synthetic mRNA protein production by up to tenfold.

24 Nov 2022

Chemically attenuated live DNA virus vaccine prevents viral infection

Rutgers researchers have devised a new way to prevent viral infections: a live-attenuated, replication-defective DNA virus vaccine that utilizes the substance centanamycin to create an altered virus for vaccine development.

From Rutgers University 22 Nov 2022

Atypical antibody shows extremely potent zika-resistant activity

A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.

22 Nov 2022

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022

New study figures out which patients will react to immunotherapy

According to a new study, patients with head and neck cancer who have more chromosome 9 genetic material in their cancer cells survive three times longer after accepting immunotherapy than patients who have less of it.

From New York University (NYU) 15 Nov 2022

Recognizing how the HIV-1 evades immune system

According to a recent study led by Andrés Finzi, a professor at the Université de Montréal and researcher at the CHUM Research Centre, the type of virus used as a model to study the effectiveness of non-neutralizing antibodies against the virus that causes AIDS, has a crucial role to play.

10 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

New technique could help fine-tune the production of useful proteins

Using an approach based on CRISPR proteins, MIT researchers have developed a new way to precisely control the amount of a particular protein that is produced in mammalian cells.

2 Nov 2022